MoonLake Immunotherapeutics (MLTX)
42.49
+0.24
(+0.57%)
USD |
NASDAQ |
Apr 26, 16:00
42.50
+0.01
(+0.02%)
After-Hours: 20:00
MoonLake Immunotherapeutics Cash from Investing (TTM): -25.18M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -25.18M |
| September 30, 2023 | -132.15M |
| June 30, 2023 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2023 | -12.68M |
| December 31, 2022 | -32.34M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-132.15M
Minimum
Sep 2023
--
Maximum
Jun 2023
-40.47M
Average
-25.18M
Median
Dec 2023
Cash from Investing (TTM) Benchmarks
| Qiagen NV | -- |
| LENZ Therapeutics Inc | -- |
| AC Immune SA | 73.11M |
| CRISPR Therapeutics AG | 374.65M |
| Addex Therapeutics Ltd | -0.0076M |